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IMPACT OF FUSARIUM MYCOTOXINS ON IN VITRO ACTIVITY OF MAJOR HEPATIC 
CYTOCHROME P450 BIOTRANSFORMATION ENZYMES IN PIGS
Introduction
Cytochrome P450 enzymes (CYP450) are catalytic oxido-reductases capable of metabolising a wide variety of endogenous and xenobiotic
compounds. A principal function of these CYP450 is to improve elimination of such substances by biotransformation to more polar and water
soluble metabolites. However, some xenobiotics can inhibit or induce CYP450 activity, and co-ingestion of these compounds with substrate
drugs can lead to an altered disposition of these substrate drugs. This has been associated with a number of clinically relevant drug-drug or
drug-food interactions. Nonetheless, regarding drug-food contaminant interactions, literature reports are scarce. Mycotoxins are highly
prevalent food and feed contaminants produced by several fungal species1. Pigs are very sensitive to the toxic effects of mycotoxins, in
particular deoxynivalenol (DON) and zearalenone (ZEA). Moreover, the inhibitory impact of T-2 toxin (T-2) on the hepatic CYP3A activity in pigs
was previously demonstrated2. In addition, the similarities between porcine and human CYP450 enzymes suggest that the pig can serve as a
suitable animal model for drug metabolism and safety studies in humans3,4. Therefore, the aim of the study was to investigate the impact of
DON, ZEA, T-2 and fumonsin B1 (FB1) on six important drug metabolising CYP450 enzymes in a porcine in vitro model.
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- Using nonlinear regression analysis with Sigmaplot® version 13
- Eight different inhibition profiles fitted for each selected mycotoxin-
substrate pair
- Determination of the model parameters: Km (Michaelis-Menten
constant), Vmax (maximal biotransformation rate), Ki (inhibitory
constant) and modification constant α and β where applicable
- Selection of model based on Akaike information criterion (AIC),
passing statistical tests for homogenity of residuals and significance
of the parameter estimates.
- Based on Ki values, in vivo direct inhibition potential of the
mycotoxins was estimated, taking into account maximal guidance
contamination levels of mycotoxins and daily feed intake of pigs.
RESULTS
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Fig 1. Non-competitive inhibition of T-2 and midazolam after
pre-incubation of microsomes with T-2. Concentrations were
0 µM (T-2-MDZ), 1 µM (T-2-MDZ-1), 10 µM (T-2-MDZ-2) and
100 µM (T-2-MDZ-3). Km= 11.3 ± 1.32 µM; Vmax= 1,899 ±
88.0 pmol/min/mg protein; Ki= 27 ± 3.97 µM.
Fig 2. Mixed partial inhibition of ZEA and midazolam,
Concentrations were 0 µM (ZEA-MDZ), 0.5 µM (ZEA-
MDZ-1), 5 µM (ZEA-MDZ-2) and 20 µM (ZEA-MDZ-3).
Km= 12.3 ± 1.1 µM; Vmax= 2,155 ± 73.2 pmol/min/mg
protein; Ki= 1.1 ± 0.22 µM; α= 3.8 ± 1.43; β= 0.3 ±
6.37*10-2.
Fig 3. Full competitive inhibition of T-2 and tolbutamide
(TB). Concentrations were 0 µM (T-2-TB), 1 µM (T-2-TB-
1), 10 µM (T-2-TB-2) and 50 µM (T-2-TB-3). Km= 805 ±
150.0 µM; Vmax= 132 ± 17.9 pmol/min/mg protein; Ki=
14.8 ± 1.45 µM.
Fig 4. Partial competitive inhibition of ZEA and tolbutamide
(TB). Concentrations were 0 µM (ZEA-TB), 0.1 µM (ZEA-
TB-1), 1 µM (ZEA-TB-2) and 10 µM (ZEA-TB-3). Km=
1,074 ± 137.9 µM; Vmax= 160.8± 15.98 pmol/min/mg
protein; Ki= 0.5 ± 4.27*10-2 µM; α= 9.5 ± 1.05.
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Fig 5. Non-competitive inhibition of ZEA and
dextromethorphan (DEX). Concentrations were 0 µM
(ZEA-DEX), 1 µM (ZEA-DEX-1), 10 µM (ZEA-DEX-2) and
100 µM (ZEA-DEX-3). Km= 2.0 ± 0.17 µM; Vmax= 1,971±
39.7 pmol/min/mg protein; Ki= 55.4 ± 5.77 µM.
Fig 6. Full mixed inhibition of FB1 and coumarin (CM).
Concentrations were 0 µM (FB1-CM), 0.1 µM (FB1-CM-
1), 1 µM (FB1-CM-2) and 5 µM (FB1-CM-3). Km= 0.9 ±
5.10*10-2 µM; Vmax= 359 ± 4.1 pmol/min/mg protein; Ki=
2.3 ± 0.34 µM; α= 14 ± 4.3.
CONCLUSIONS
- ZEA can directly inhibit CYP3A, CYP2C and CYP2D enzymes with 
high potency towards CYP3A and CYP2C as reflected in their Ki 
values (1.1 and 0.5 µM respectively).
- FB1 is a potent inhibitor of coumarin hydroxylase indicating 
inhibition potential towards CYP2A.
- T-2 is a time dependent inhibitor of CYP3A and a competitive 
inhibitor for CYP2C.
- DON could not inhibit any of the reactions significantly.
- Based on the volume of distribution, daily feed intake, maximal
guidance levels of mycotoxins and assuming complete oral
bioavailability, expected in vivo mycotoxin plasma concentrations are
20-400 times lower then Ki values. Therefore, direct inhibition in vivo
seems unlikely. However, hepatic cellular concentrations can be
higher then estimated plasma concentrations. In addition, the micro-
environment can influence interactions between toxin and enzyme
significantly. Moreover, mycotoxins can possibly alter CYP450 in vivo
by exerting a regulatory effect, depending on the mycotoxin.
- Future trials are needed to investigate the in vivo impact
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